SCHEMBL6443626

SCHEMBL6443626

COC(=O)c1cccc(Cn2nnc(-c3ccc(F)c4c(C(=O)C(=O)N5CCN(C(=O)c6ccccc6)CC5)c[nH]c34)n2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.45
CYP3A4 P08684 2/20 0.43
CYP2D6 P10635 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C8 P10632 1/20 0.42
CYP2B6 P20813 1/20 0.42
CYP2C19 P33261 1/20 0.42
KCNH2 Q12809 1/20 0.42
OPRD1 P41143 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
ALDH1A1 P00352 3/20 0.40
LMNA P02545 3/20 0.40
HTT P42858 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
MMP13 P45452 1/20 0.35
MAPK10 P53779 2/20 0.35
MAPK8 P45983 1/20 0.35
KDM4E B2RXH2 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6442773 0.93 CYP2C9 (0.46) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL6440924 0.92 SMN1; SMN2 (0.46) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL6443804 0.91 CYP2C9 (0.42) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL6442058 0.90 CYP2C9 (0.46) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL6443740 0.89 CYP2C9 (0.46) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL6440957 0.86 CYP2C9 (0.44) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL6441372 0.86 CYP2C9 (0.44) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL6442558 0.85 CYP2C9 (0.49) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL6442503 0.84 CYP2C9 (0.46) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL6445395 0.84 CYP2C9 (0.47) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2002004440-A9 COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2005-11-03 WO claimed
EP-1299382-B1 COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2005-09-21 EP claimed
US-6573262-B2 Compounds for treating mammals infected with HIV virus BRISTOL-MYERS SQIBB COMPANY 2003-06-03 US claimed
US-20030069245-A1 Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2003-04-10 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069245-A1 Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives IDO1, IDO2, ITPA CYP2C9 2370/4885CYP3A4 469/4885CYP2D6 831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.